Sarclisa, known generically as isatuximab, is a monoclonal antibody used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. It works by targeting and binding to a specific protein found on the surface of cancer cells, called CD38, which plays a significant role in the growth and survival of myeloma cells. By attaching to these cells, Sarclisa helps to mark them for destruction by the body's immune system. It is often used in combination with other medications, such as dexamethasone and certain chemotherapy drugs, to enhance its effectiveness. Sarclisa is administered through intravenous infusion and is typically recommended for patients who have received at least one prior therapy. Its approval and use have provided a new avenue for the treatment of multiple myeloma, offering hope to patients with this challenging condition.